Moderna (MRNA) Stock: Buy, Sell, or Hold?
MRNA - Moderna, Inc. Common Stock
$154.04
-4.03 (-2.55%)
▼
5d:
+6.99%
30d:
-11.66%
90d:
+140.84%
HOLD
MODERATE Confidence
Analysis Updated: Sep 18, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 1, 2026 at $148.71 · last confirmed Sep 15, 2026
Strength: 9.0/10
Get Alerted When MRNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: MRNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: MRNA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: MRNA is currently trading at $154.04, which is considered slightly high relative to its 30-day fair value range of $89.53 to $163.16.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $130.38, while resistance sits at $161.96.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $119.56. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, MRNA is in a strong uptrend. Immediate support is located at $130.38, while resistance sits at $161.96.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. However, the stock is trading significantly above the average Wall Street target of $119.56. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$89.53 -
$163.16
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.3%
Protect Your Profits
Holding MRNA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 22.4% above Wall St target ($119.56)
- NEUTRAL: Bottoming setup forming (42/100) — watch for confirmation
Trading Range Analysis
30-Day Trading Range
$89.53 -
$163.16
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$130.38
Resistance Level
$161.96
Current Trend
Strong Uptrend
Technical data as of
Sep 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-32.18
Wall Street Target
$119.56
(-22.4%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
-85.1%
Profit Margin
-141.4%
Share & Embed Analysis
Last updated: September 21, 2026 5:34 AM ET
Data refreshes hourly during market hours. Next update: 6:34 AM
Data refreshes hourly during market hours. Next update: 6:34 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 62 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 49 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$569 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$59 | 59 HOLD |
Advanced MRNA Option Strategies
Professional options setups generated by AI based on today's MRNA price and gamma walls.
